



December 30, 2014

Horizon Technology Finance Provides \$5 Million Venture Loan to Interleukin Genetics

FARMINGTON, CT and WALTHAM, MA / ACCESSWIRE / December 30, 2014 / Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and cleantech industries, today announced it has closed a \$5 million venture loan for Interleukin Genetics, Inc. (OTCQB: ILIU) ("Interleukin"), a genetics-based personalized health testing company. Interleukin will use the proceeds for working capital purposes.

"We are pleased to provide Interleukin the growth capital to support the company's commercialization efforts for its suite of genetic test products," stated Gerald A. Michaud, President of Horizon. "Interleukin's technology, market opportunity, and key partnerships make for a compelling investment opportunity."

Dr. Kenneth Kornman, Chief Executive Officer of Interleukin Genetics, stated, "Having the right capital at the right time is critical for a growth stage company. Horizon's flexible financing solution, team of venture lending experts, and smooth and efficient loan closing have provided Interleukin with the strategic capital necessary for its continued growth."

About Horizon Technology Finance

Horizon Technology Finance Corporation is a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and cleantech industries. The investment objective of Horizon is to maximize total returns by generating current income from a portfolio of directly originated secured loans as well as capital appreciation from warrants that it receives when making such loans. Headquartered in Farmington, Connecticut, Horizon has regional offices in Walnut Creek, California and Reston, Virginia. Horizon's common stock trades on the NASDAQ Global Select Market under the ticker symbol "HRZN". To learn more, please visit www.horizontechnologyfinancecorp.com.

About Interleukin Genetics

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health related conditions. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics' flagship products include its proprietary PerioPredict(TM) genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA, and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Act (CLIA).

Forward-Looking Statements

Statements included herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in our filings with the Securities and Exchange Commission. Horizon undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

CONTACT:

Horizon Technology Finance

Christopher M. Mathieu

Chief Financial Officer

(860) 676-8653

chris@horizontechfinance.com

Investor Relations and Media Contacts:

The IGB Group

Matt Steinberg / Leon Berman

(212) 477-8261 / (212) 477-8438

msteinberg@igbir.com / lberman@igbir.com

SOURCE: Horizon Technology Finance Corporation

News Provided by Acquire Media